GFAP and UCHL1 in Non-traumatic SAH: The Story thus Far. A Systematic Review of the Literature.

Autor:	Psochias F; Department of Neurosurgery, National and Kapodistrian University of Athens, Athens, Greece.; Clinical and Experimental Neuroscience Research Group, Department of Neurosurgery, National and Kapodistrian University of Athens, Athens, Greece., Mavrovounis G; Department of Neurosurgery, National and Kapodistrian University of Athens, Athens, Greece.; Clinical and Experimental Neuroscience Research Group, Department of Neurosurgery, National and Kapodistrian University of Athens, Athens, Greece.; Department of Neurosurgery, Faculty of Medicine, University of Thessaly, Larissa, Greece., Stranjalis G; Department of Neurosurgery, National and Kapodistrian University of Athens, Athens, Greece., Kalamatianos T; Department of Neurosurgery, National and Kapodistrian University of Athens, Athens, Greece.; Clinical and Experimental Neuroscience Research Group, Department of Neurosurgery, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	CNS & neurological disorders drug targets [CNS Neurol Disord Drug Targets] 2024; Vol. 23 (11), pp. 1328-1344.
DOI:	10.2174/0118715273276472231116104549
Abstrakt:	Objective: Non-traumatic subarachnoid hemorrhage (SAH) is associated with a high percentage of misdiagnosis and poor prognosis. Biomarkers could be useful in the identification, treatment/management guidance, and outcome improvement of SAH patients. The current systematic review aims to investigate the potential role of biomarkers GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (Ubiquitin C-Terminal Hydrolase L1) in the diagnosis and prognosis of non-traumatic SAH. Methods: A systematic search of PubMed, Scopus, and Web of Science databases was conducted from their inception through February 2023. Results: 17 studies met the inclusion criteria and were included in this review. The vast majority of the included studies (82%) were on GFAP. Most studies used blood and/or CSF samples and incorporated multiple measurements through the initial hospitalization days. The majority of identified studies reported significantly higher levels of GFAP and UCHL1 in SAH patients with poor outcomes. There was notable variation in the specimen type and the timing of sampling. Conclusion: Quantification of GFAP and UCHL1 through the initial days of hospitalization shows promise in the prediction of SAH patient outcomes. Further research is nevertheless warranted to confirm these findings and further clarify the use of the two biomarkers in SAH diagnosis and the prediction of severity and secondary events. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu